Novocure Ltd (NVCR) Stock Analysis

Novocure Ltd (NVCR) is a publicly traded company in the HEALTHCARE sector. It trades at $15.82, carries a market capitalization of $1.92B. This page summarizes the public market data, fundamentals, and frequently asked questions for NVCR, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - MEDICAL DEVICES

Exchange: NASDAQ

Key Metrics

Market Sentiment

Novocure Ltd currently has a Neutral sentiment score of 0.11.

About Novocure Ltd

Novocure Ltd is a pioneering oncology company based in Saint Helier, Jersey, dedicated to transforming cancer treatment through its proprietary tumor-treating fields (TTFields) therapy, highlighted by its flagship product, Optune. This innovative approach targets and disrupts the division of cancer cells, with current approvals for specific solid tumors such as glioblastoma multiforme and mesothelioma. As Novocure enhances its clinical trial portfolio and research initiatives, it aims to soli...

GNG Research Analysis

GNG Research scores Novocure Ltd (NVCR) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for NVCR.

Frequently Asked Questions

Does NVCR pay dividends?

Novocure Ltd (NVCR) does not currently pay a regular dividend.

What is NVCR's market cap?

Novocure Ltd (NVCR) has a market capitalization of $1.92B with a current stock price of $15.82.